抗体药物偶联物对膀胱肿瘤的作用机制及研究进展
The Mechanism and Research Progress of Antibody-Drug Conjugates in the Treatment of Bladder Tumors
DOI: 10.12677/acm.2025.1571979, PDF,   
作者: 严聪聪：赣南医科大学第一临床医学院，江西 赣州；赣南医科大学泌尿外科研究所，江西 赣州；伍耿青*：赣南医科大学第一临床医学院，江西 赣州；赣南医科大学泌尿外科研究所，江西 赣州；赣南医科大学第一附属医院泌尿外科，江西 赣州
关键词: 膀胱癌；抗体药物偶联物；靶向药物；Bladder Cancer； Antibody-Drug Conjugate； Targeted Drug
摘要: 膀胱癌(BC)好发于老年男性，是一种发病率高、死亡率高、且晚期或转移性膀胱癌治疗手段少的疾病。目前主流的辅助治疗还是以顺铂为核心的化疗方案，但患者仍易复发转移，且易耐药和副作用明显，依从性差。抗体药物偶联物(ADC)是一种将单克隆抗体与细胞毒性药物通过化学连接子结合的新型靶向药物，有着精准性高、高效低毒性等特点，可以有效发挥抗癌作用，提高患者的获益率。本文就ADC的作用机制进行阐述，回顾国内外ADC在BC治疗中的应用效果及问题。
Abstract: Bladder cancer (BC), which occurs predominantly in elderly men, is a disease with high morbidity and mortality, and few treatment options for advanced or metastatic bladder cancer. At present, the mainstream adjuvant therapy is still cisplatin as the core chemotherapy regimen, but patients are still prone to recurrence and metastasis, and are prone to drug resistance, obvious side effects, and poor compliance. Antibody-drug conjugate (ADC) is a new type of targeted drug that combines monoclonal antibody with cytotoxic drug through chemical linker. ADC has the characteristics of high precision, high efficiency and low toxicity, which can effectively play an anti-cancer effect and improve the benefit rate of patients. In this paper, the mechanism of ADC is described, and the application effect and problems of ADC in the treatment of BC at home and abroad are reviewed.
文章引用：严聪聪, 伍耿青. 抗体药物偶联物对膀胱肿瘤的作用机制及研究进展[J]. 临床医学进展, 2025, 15(7): 223-232. https://doi.org/10.12677/acm.2025.1571979

参考文献

[1] Dobruch, J. and Oszczudłowski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina, 57, Article 749. [Google Scholar] [CrossRef] [PubMed]
[2] Lopez-Beltran, A., Cookson, M.S., Guercio, B.J., et al. (2024) Advances in Diagnosis and Treatment of Bladder Cancer. BMJ, 384, e076743. [Google Scholar] [CrossRef] [PubMed]
[3] von der Maase, H., Sengelov, L., Roberts, J.T., Ricci, S., Dogliotti, L., Oliver, T., et al. (2005) Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer. Journal of Clinical Oncology, 23, 4602-4608. [Google Scholar] [CrossRef] [PubMed]
[4] Tran, L., Xiao, J., Agarwal, N., Duex, J.E. and Theodorescu, D. (2021) Advances in Bladder Cancer Biology and Therapy. Nature Reviews Cancer, 21, 104-121. [Google Scholar] [CrossRef] [PubMed]
[5] Thomas, J., Sun, M., Getz, T., Ho, B., Nauseef, J.T. and Tagawa, S.T. (2023) Antibody-Drug Conjugates for Urothelial Carcinoma. Urologic Oncology: Seminars and Original Investigations, 41, 420-428. [Google Scholar] [CrossRef] [PubMed]
[6] Nguyen, T.D., Bordeau, B.M. and Balthasar, J.P. (2023) Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15, Article 713. [Google Scholar] [CrossRef] [PubMed]
[7] Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. (2022) Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy. Signal Transduction and Targeted Therapy, 7, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[8] Maecker, H., Jonnalagadda, V., Bhakta, S., Jammalamadaka, V. and Junutula, J.R. (2023) Exploration of the Antibody-Drug Conjugate Clinical Landscape. mAbs, 15, Article 2229101. [Google Scholar] [CrossRef] [PubMed]
[9] Hammood, M., Craig, A. and Leyton, J. (2021) Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development. Pharmaceuticals, 14, Article 674. [Google Scholar] [CrossRef] [PubMed]
[10] Samantasinghar, A., Sunildutt, N.P., Ahmed, F., Soomro, A.M., Salih, A.R.C., Parihar, P., et al. (2023) A Comprehensive Review of Key Factors Affecting the Efficacy of Antibody Drug Conjugate. Biomedicine & Pharmacotherapy, 161, Article 114408. [Google Scholar] [CrossRef] [PubMed]
[11] Kang, H.W., Kim, W., Choi, W. and Yun, S.J. (2020) Tumor Heterogeneity in Muscle-Invasive Bladder Cancer. Translational Andrology and Urology, 9, 2866-2880. [Google Scholar] [CrossRef] [PubMed]
[12] Cheng, X. (2024) A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes, 15, Article 903. [Google Scholar] [CrossRef] [PubMed]
[13] Sanguedolce, F., Zanelli, M., Palicelli, A., Bisagni, A., Zizzo, M., Ascani, S., et al. (2023) HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role. International Journal of Molecular Sciences, 24, Article 3720. [Google Scholar] [CrossRef] [PubMed]
[14] Yan, M., Schwaederle, M., Arguello, D., Millis, S.Z., Gatalica, Z. and Kurzrock, R. (2015) HER2 Expression Status in Diverse Cancers: Review of Results from 37,992 Patients. Cancer and Metastasis Reviews, 34, 157-164. [Google Scholar] [CrossRef] [PubMed]
[15] Deeks, E.D. (2021) Disitamab Vedotin: First Approval. Drugs, 81, 1929-1935. [Google Scholar] [CrossRef] [PubMed]
[16] Yu, J., Fang, T., Yun, C., et al. (2022) Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Frontiers in Molecular Biosciences, 9, Article 847835. [Google Scholar] [CrossRef] [PubMed]
[17] Domb, C., Garcia, J.A., Barata, P.C., Mendiratta, P., Rao, S. and Brown, J.R. (2024) Systematic Review of Recent Advancements in Antibody-Drug and Bicycle Toxin Conjugates for the Treatment of Urothelial Cancer. Therapeutic Advances in Urology, 16, 1-23. [Google Scholar] [CrossRef] [PubMed]
[18] Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., et al. (2021) Open-Label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research, 27, 43-51. [Google Scholar] [CrossRef] [PubMed]
[19] Xu, J., Zhang, H., Zhang, L., et al. (2023) Real-World Effectiveness and Safety of RC48-ADC alone or in Combination with PD-1 Inhibitors for Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Multicenter, Retrospective Clinical Study. Cancer Medicine, 12, 21159-21171. [Google Scholar] [CrossRef] [PubMed]
[20] Zhou, L., Yang, K.W., Zhang, S., et al. (2025) Disitamab Vedotin Plus Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (RC48-C014): A Phase Ib/II Dose-Escalation and Dose-Expansion Study. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 36, 331-339. [Google Scholar] [CrossRef] [PubMed]
[21] Hong, X., Chen, X., Wang, H., Xu, Q., Xiao, K., Zhang, Y., et al. (2023) A HER2-Targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer. Advanced Science, 10, Article 2302377. [Google Scholar] [CrossRef] [PubMed]
[22] National Institute of Diabetes and Digestive and Kidney Diseases (2012) Trastuzumab Deruxtecan, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.
[23] Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S., González-Martín, A., et al. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients with Her2-Expressing Solid Tumors: Primary Results from the DESTINY-Pantumor02 Phase II Trial. Journal of Clinical Oncology, 42, 47-58. [Google Scholar] [CrossRef] [PubMed]
[24] Swain, S.M., Nishino, M., Lancaster, L.H., Li, B.T., Nicholson, A.G., Bartholmai, B.J., et al. (2022) Multidisciplinary Clinical Guidance on Trastuzumab Deruxtecan (T-DXd)-Related Interstitial Lung Disease/Pneumonitis—Focus on Proactive Monitoring, Diagnosis, and Management. Cancer Treatment Reviews, 106, Article 102378. [Google Scholar] [CrossRef] [PubMed]
[25] Tarantino, P., Modi, S., Tolaney, S.M., Cortés, J., Hamilton, E.P., Kim, S., et al. (2021) Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncology, 7, 1873-1881. [Google Scholar] [CrossRef] [PubMed]
[26] Chatterjee, S., Sinha, S. and Kundu, C.N. (2021) Nectin Cell Adhesion Molecule-4 (NECTIN-4): A Potential Target for Cancer Therapy. European Journal of Pharmacology, 911, Article 174516. [Google Scholar] [CrossRef] [PubMed]
[27] Wong, J.L., Rosenberg, J.E. (2021) Targeting Nectin-4 by Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma. Expert Opinion on Biological Therapy, 21, 863-873. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, Y., Han, X., Li, L., Zhang, Y., Huang, X., Li, G., et al. (2021) Role of Nectin-4 Protein in Cancer (Review). International Journal of Oncology, 59, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[29] Bouleftour, W., Sargos, P., Magne, N. (2023) Nectin-4: A Tumor Cell Target and Status of Inhibitor Development. Current Oncology Reports, 25, 181-188. [Google Scholar] [CrossRef] [PubMed]
[30] National Institute of Diabetes and Digestive and Kidney Diseases (2012) Enfortumab Vedotin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.
[31] Alt, M., Stecca, C., Tobin, S., et al. (2020) Enfortumab Vedotin in Urothelial Cancer. Therapeutic Advances in Urology, 12, 1-10. [Google Scholar] [CrossRef] [PubMed]
[32] Powles, T., Rosenberg, J.E., Sonpavde, G.P., et al. (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. The New England Journal of Medicine, 384, 1125-1135. [Google Scholar] [CrossRef] 
[33] Powles, T., Valderrama, B.P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., et al. (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England Journal of Medicine, 390, 875-888. [Google Scholar] [CrossRef] [PubMed]
[34] National Institute of Diabetes and Digestive and Kidney Diseases (2012) Sacituzumab Govitecan, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.
[35] Veeraballi, S., Khawar, Z., Aslam, H.M. and Muzaffar, M. (2022) Role of Sacituzumab Govitecan in Solid Tumors. Journal of Oncology Pharmacy Practice, 28, 1617-1623. [Google Scholar] [CrossRef] [PubMed]
[36] Bardia, A., Messersmith, W.A., Kio, E.A., Berlin, J.D., Vahdat, L., Masters, G.A., et al. (2021) Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase I/II IMMU-132-01 Basket Trial. Annals of Oncology, 32, 746-756. [Google Scholar] [CrossRef] [PubMed]
[37] Tagawa, S.T., Balar, A.V., Petrylak, D.P., Kalebasty, A.R., Loriot, Y., Fléchon, A., et al. (2021) TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing after Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of Clinical Oncology, 39, 2474-2485. [Google Scholar] [CrossRef] [PubMed]
[38] Kapoor, A., Niazi, T., Noonan, K., Rendon, R.A., Alimohamed, N., Kassouf, W., et al. (2022) 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium: Meeting Highlights. Canadian Urological Association Journal, 16, 125-131. [Google Scholar] [CrossRef] [PubMed]
[39] McGregor, B.A., Sonpavde, G.P., Kwak, L., et al. (2024) The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 35, 91-97. [Google Scholar] [CrossRef] [PubMed]
[40] Schlam, I., Tarantino, P. and Tolaney, S.M. (2023) Managing Adverse Events of Sacituzumab Govitecan. Expert Opinion on Biological Therapy, 23, 1103-1111. [Google Scholar] [CrossRef] [PubMed]
[41] Tsuchikama, K., Anami, Y., Ha, S.Y.Y., et al. (2024) Exploring the Next Generation of Antibody-Drug Conjugates. Nature Reviews. Clinical Oncology, 21, 203-223. [Google Scholar] [CrossRef] [PubMed]
[42] Khoury, R., Saleh, K., Khalife, N., et al. (2023) Mechanisms of Resistance to Antibody-Drug Conjugates. International Journal of Molecular Sciences, 24, Article 9674. [Google Scholar] [CrossRef] [PubMed]
[43] Chen, Y., Xu, Y., Shao, Z. and Yu, K. (2022) Resistance to Antibody-Drug Conjugates in Breast Cancer: Mechanisms and Solutions. Cancer Communications, 43, 297-337. [Google Scholar] [CrossRef] [PubMed]
[44] Pupa, S.M., Ligorio, F., Cancila, V., Franceschini, A., Tripodo, C., Vernieri, C., et al. (2021) HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers, 13, Article 4778. [Google Scholar] [CrossRef] [PubMed]
[45] Phillips, G.D.L., Fields, C.T., Li, G., Dowbenko, D., Schaefer, G., Miller, K., et al. (2014) Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. Clinical Cancer Research, 20, 456-468. [Google Scholar] [CrossRef] [PubMed]
[46] Filho, O.M., Viale, G., Stein, S., et al. (2021) Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Dis-covery, 11, 2474-2487. [Google Scholar] [CrossRef] 
[47] Ríos-Luci, C., García-Alonso, S., Díaz-Rodríguez, E., Nadal-Serrano, M., Arribas, J., Ocaña, A., et al. (2017) Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Research, 77, 4639-4651. [Google Scholar] [CrossRef] [PubMed]
[48] Hamblett, K.J., Jacob, A.P., Gurgel, J.L., Tometsko, M.E., Rock, B.M., Patel, S.K., et al. (2015) SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. Cancer Research, 75, 5329-5340. [Google Scholar] [CrossRef] [PubMed]
[49] Abelman, R.O., Wu, B., Spring, L.M., et al. (2023) Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers, 15, Article 1278. [Google Scholar] [CrossRef] [PubMed]
[50] Coates, J.T., Sun, S., Leshchiner, I., et al. (2021) Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. Cancer Discovery, 11, 2436-2445. [Google Scholar] [CrossRef] 
[51] Guidi, L., Pellizzari, G., Tarantino, P., et al. (2023) Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers, 15, Article 1130. [Google Scholar] [CrossRef] [PubMed]
[52] Glaviano, A., Foo, A.S.C., Lam, H.Y., Yap, K.C.H., Jacot, W., Jones, R.H., et al. (2023) PI3K/Akt/mTOR Signaling Transduction Pathway and Targeted Therapies in Cancer. Molecular Cancer, 22, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[53] Wang, P., Mak, V.C. and Cheung, L.W. (2023) Drugging IGF-1R in Cancer: New Insights and Emerging Opportunities. Genes & Diseases, 10, 199-211. [Google Scholar] [CrossRef] [PubMed]
[54] Katoh, M. (2017) Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, a Receptor Tyrosine Kinase-Like Molecule Involved in WNT and Vascular Endothelial Growth Factor Signaling: Effects on Cancer Stem Cells, Tumor Microenvironment and Whole-Body Homeostasis. Annals of Translational Medicine, 5, 462-462. [Google Scholar] [CrossRef] [PubMed]
[55] Li, J.Y., Perry, S.R., Muniz-Medina, V., Wang, X., Wetzel, L.K., Rebelatto, M.C., et al. (2019) A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell, 35, 948-949. [Google Scholar] [CrossRef] [PubMed]
[56] Giugliano, F., Corti, C., Tarantino, P., Michelini, F. and Curigliano, G. (2022) Bystander Effect of Antibody-Drug Conjugates: Fact or Fiction? Current Oncology Reports, 24, 809-817. [Google Scholar] [CrossRef] [PubMed]
[57] Hartley, J.A. (2020) Antibody-Drug Conjugates (ADCs) Delivering Pyrrolobenzodiazepine (PBD) Dimers for Cancer Therapy. Expert Opinion on Biological Therapy, 21, 931-943. [Google Scholar] [CrossRef] [PubMed]
[58] Li, C., Shi, K., Zhao, S., Liu, J., Zhai, Q., Hou, X., et al. (2024) Natural-Source Payloads Used in the Conjugated Drugs Architecture for Cancer Therapy: Recent Advances and Future Directions. Pharmacological Research, 207, Article 107341. [Google Scholar] [CrossRef] [PubMed]
[59] Abraham, J., Montero, A.J., Jankowitz, R.C., et al. (2019) Safety and Efficacy of T-DM1 Plus Neratinib in Patients with Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 2601-2609. [Google Scholar] [CrossRef] 
[60] Zhang, L., Yan, Y., Gao, Y., Chen, Y., Yu, J., Ren, N., et al. (2024) Antibody-Drug Conjugates and Immune Checkpoint Inhibitors in Cancer Treatment: A Systematic Review and Meta-Analysis. Scientific Reports, 14, Article No. 22357. [Google Scholar] [CrossRef] [PubMed]

为你推荐